Questcor Pharmaceuticals Inc (QCOR.O)
17 May 2013
|Market Cap (Mil.):||$2,195.17|
|Shares Outstanding (Mil.):||59.55|
- Questcor Pharmaceuticals Inc's first-quarter profit lagged analysts' expectations as sales of its Acthar drug fell due to Medicaid reimbursement changes but the company said sales have bounced back in the current quarter.
April 30 - Questcor Pharmaceuticals Inc's first-quarter profit missed Street expectations as the number of prescriptions fell for its top-selling drug, Acthar, sending its shares down about 11 percent in after market trade.
|GlaxoSmithKline plc (GSK.L)||1,712.50p||+5.00|
|Novartis AG (NOVN.VX)||CHF71.75||-0.45|
|Sanofi SA (SASY.PA)||€84.50||-0.12|
|Pfizer Inc. (PFE.N)||$28.96||-0.29|
|Johnson & Johnson (JNJ.N)||$88.09||+0.64|
|Roche Holding Ltd. (ROG.VX)||CHF247.00||+1.00|
|Merck & Co., Inc. (MRK.N)||$45.99||-0.38|
|Abbott Laboratories (ABT.N)||$36.59||-0.24|
|Bayer AG (BAYGn.DE)||€83.79||-1.01|
|Bayer AG (BAYE.F)||--||--|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of QUESTCOR PHARMACEUTICALS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
Provider: ValuEngine, Inc.
Provider: Market Edge
Provider: S&P Capital IQ Factual Report
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.